Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

Study Identifier
S187.4.001
CT.gov Identifier
NCT00141518
EudraCT Identifier
2005-002654-21
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Parkinson's Disease
    • Study Drug
  • Levodopa-carbidopa intestinal gel (LCIG)
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    \- Advanced idiopathic Parkinson's disease
    Exclusion Criteria:
    \- Other diseases which might influence compliance or participation in the study

    Protocol Summary

    The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.

    Study Locations

    No locations found.